Methadone and prolongation of QT interval
- there is a risk of QT interval prolongation in patients taking methadone, especially those on high doses (1)
- there is evidence that very-high-dose methadone may be associated with torsade de pointes (2)
- recommended that patients with the following risk factors for QT interval prolongation are carefully monitored whilst taking methadone:
- heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 inhibitors, or medicines with the potential to cause QT interval prolongation (1)
- also any patient requiring more than 100mg of methadone per day should be closely monitored (1)
- the RCGP guidance also notes that the risk of QT-interval prolongation may be dose-dependent (3)
- "..methadone may be a risk factor for QT prolongation and torsade de pointes with a possible dose-dependent action... recommends monitoring for patients on high dose methadone (>100 mg daily) and with other QT interval prolongation risk factors where appropriate.."
- heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 inhibitors, or medicines with the potential to cause QT interval prolongation (1)
Reference:
- (1) Current Problems in Pharmacovigilance 2006;31:1-12.
- (2) Krantz MJ et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002 Sep 17;137(6):501-4.
- (3) RCGP (2007). Drug misuse and dependence: UK guidelines on clinical management
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.